Blood Phoenixin-14 Levels and Echocardiographic Findings in Infants of Diabetic Mothers
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age1-5
SponsorKonya City Hospital
About this trial
In this study, the investigators hypothesize that echocardiographic pathologies observed in infants of diabetic mothers are associated with elevated serum phoenixin-14 levels.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Infants of diabetic mothers
Healthy term infants
Disqualifiers
Infants whose families did not provide consent
Infants with a syndromic appearance or congenital heart disease
Trial design
Design model
Parallel
Treatments tested in this trial
echocardiographic evaluation and blood phoenixin-14 level
Diagnostic testFor participants who provide consent, blood samples will be collected at 6 hours postpartum. Additionally, infants included in the study will undergo an echocardiographic evaluation by a pediatric cardiologist between postnatal days 3 and 5.
Treatment groups
84 Participants
are divided into 2 treatment groupsGroup A: Baby of mother diagnosed with GDMExperimental treatment 1 intervention
Group B: healthy infantsExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Correlation between serum phoenixin-14 levels and echocardiographic pathologies in infants of diabetic mothers.
Measurement Variables: * Serum phoenixin-14 concentration (pg/mL). * Presence of pathologies related to echocardiographic intraventricular septum thickness Analysis Metric: Assessment of the relationship between serum phoenixin-14 levels and echocardiographic intraventricular septum thickness. Data Collection Method: Serum phoenixin-14 levels will be measured using a specific immunoassay, and echocardiographic evaluations will be conducted by a pediatric cardiologist.
Time frame
postnatal 5 daysSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov